Creating a targeted treatment to prevent artery re-narrowing after procedures.
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment
This study is testing a new treatment that uses tiny particles to deliver medicine directly to damaged arteries after procedures like angioplasty, helping to keep them open and healthy so you can avoid future problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10897055 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of treatment that uses tiny particles to deliver medication directly to damaged arteries after procedures like angioplasty. The goal is to prevent the arteries from narrowing again, a common problem known as restenosis. The treatment involves a special nanotherapeutic that releases nitric oxide, which helps maintain healthy blood vessels and reduces the risk of complications. Patients will receive this treatment intravenously, allowing it to target the specific area of injury effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with severe atherosclerosis who are undergoing procedures like angioplasty.
Not a fit: Patients who do not have atherosclerosis or are not undergoing vascular interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve recovery outcomes for patients undergoing vascular interventions by reducing the chances of artery re-narrowing.
How similar studies have performed: Previous research has shown promise in using targeted nanotherapeutics for vascular applications, indicating a potential for success with this novel approach.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Kibbe, Melina Rae — University of Virginia
- Study coordinator: Kibbe, Melina Rae
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.